21-Hydroxylase Deficiency Detected in Neonatal Screening: High Probability of False Negativity in Late Onset Form

Abstract

Aim Despite the high sensitivity of neonatal screening in detecting the classical form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, one of the unclear issues is identifying asymptomatic children with late onset forms. The aim of this nationwide study was to analyse the association between genotype and screened level of 17-hydroxyprogesterone in patients with the late onset form of 21-hydroxylase deficiency and to quantify false negativity.

Methods In the Czech Republic, 1,866,129 neonates were screened (2006–2022). Among this cohort, 159 patients were confirmed to suffer from 21-hydroxylase deficiency, employing the 17-hydroxyprogesterone birthweight/gestational age-adjusted cut-off limits, and followed by the genetic confirmation. The screening prevalence was 1:11,737. Another 57 patients who were false negative in neonatal screening were added to this cohort based on later diagnosis by clinical suspicion. To our knowledge, such a huge nationwide cohort of false negative patients has not been documented before.

Results Overall, 57 patients escaped from neonatal screening in the monitored period. All false negative patients had milder forms. Only one patient had simple virilising form and 56 patients had the late onset form. The probability of false negativity in the late onset form was 76.7%. The difference in 17-hydroxyprogesterone screening values was statistically significant (p<0.001) between severe forms (median 478.8 nmol/L) and milder (36.2 nmol/L) forms. Interestingly, the higher proportion of females with milder forms was statistically significant compared with the general population.

Conclusions A negative neonatal screening result does not exclude milder forms of 21-hydroxylase deficiency during the differential diagnostic procedure of children with precocious pseudopuberty.

Keywords

congenital adrenal hyperplasia - genotype - Czech Republic

Publication History

Received: 05 June 2024
Received: 07 August 2024

Accepted: 24 September 2024

Accepted Manuscript online:
02 October 2024

Article published online:
12 November 2024

• References

• 1 Votava F, Novotna D, Kracmar P. et al. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur J Pediatr 2012; 171: 935-940
• 2 Zetterström RH, Karlsson L, Falhammar H. et al. Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Int J Neonatal Screen 2020; 6: 71
• 3 Castro PS, Rassi TO, Araujo RF. et al. High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening. J Pediatr Endocrinol Metab 2019; 32: 499-504
• 4 Livadas S, Dracopoulou M, Dastamani A. et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol (Oxf) 2015; 82: 543-549
• 5 Pode-Shakked N, Blau A, Pode-Shakked B. et al. Combined gestational age-and birth weight-adjusted cutoffs for newborn screening of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2019; 104: 3172-3180
• 6 Dunnen JT, Dalgleish R, Maglott DR. et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat 2006; 37: 564-569
• 7 Gidlöf S, Wedell A, Guthenberg C. et al. Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study. JAMA Pediatr 2014; 168: 567-574
• 8 Votava F, Török D, Kovács J. et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. Eur J Endocrinol 2005; 152: 869-874
• 9 Gialluisi A, Menabò S, Baldazzi L. et al. A genetic epidemiology study of congenital adrenal hyperplasia in Italy. Clin Genet 2018; 93: 223-227
• 10 Skordis N, Shammas C, Efstathiou E. et al. Endocrine profile and phenotype-genotype correlation in unrelated patients with non-classical congenital adrenal hyperplasia. Clin Biochem 2011; 44: 959-963
• 11 Lai F, Srinivasan S, Wiley V. Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme. Int J Neonatal Screen 2020; 6: 63
• 12 Stroek K, Ruiter A, van der Linde A. et al. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study. J Clin Endocrinol Metab 2021; 106: e4487-e4496